Trade Names:Prozac- Capsules 10 mg- Capsules 20 mg- Capsules 40 mg- Solution, oral 20 mg per 5 mL
Trade Names:Prozac Weekly- Capsules, delayed-release 90 mg
Trade Names:Sarafem- Tablets 10 mg- Tablets 15 mg- Tablets 20 mg
Trade Names:Selfemra- Capsules 10 mg- Capsules 20 mgApo-Fluoxetine (Canada)CO Fluoxetine (Canada)FXT (Canada)Gen-Fluoxetine (Canada)Novo-Fluoxetine (Canada)Nu-Fluoxetine (Canada)PMS-Fluoxetine (Canada)ratio-Fluoxetine (Canada)Sandoz Fluoxetine (Canada)
Presumed to be linked to inhibition of CNS neuronal reuptake of serotonin.
T max is 6 to 8 h. C max is 15 to 55 ng/mL (40 mg dose). Food does not affect systemic bioavailability, but may delay absorption 1 to 2 h.
Protein binding is approximately 94.5%.
Major metabolite is norfluoxetine (active) formed by demethylation. Primary route is hepatic (CYP2D6).
The half-life is 1 to 16 days, including active metabolite. Primary route is renal excretion of inactive metabolites.
Routine dosage adjustment is not needed.Hepatic Function Impairment
The half-life for fluoxetine and norfluoxetine is prolonged.Elderly
In healthy subjects, the disposition of fluoxetine did not differ in patients older than 65 yr of age compared with younger patients.
Major depressive disorder; depressive episodes associated with bipolar I disorder (only in combination with olanzapine); obsessive-compulsive disorder (OCD); bulimia nervosa; panic disorder; treatment-resistant depression (only in combination with olanzapine).Sarafem , Selfemra
Premenstrual dysphoric disorder.
Alcoholism; borderline personality disorder; diabetic neuropathy; fibromyalgia; hot flashes; nocturnal enuresis; postherpetic neuralgia; posttraumatic stress disorder; Raynaud phenomenon; second-line prophylaxis of migraines.
Concurrent thioridazine use or within a minimum of 5 wk after discontinuing fluoxetine; concurrent use with or within a minimum of 14 days of discontinuing an MAOI (allow at least 5 wk after stopping fluoxetine before starting an MAOI); concurrent pimozide use; hypersensitivity to any component of the product.
PO Initial: 60 mg daily in the morning; for some patients it may be advisable to titrate up to this target dose over several days.Depressive Episodes Associated With Bipolar I DisorderAdults
PO Initial: fluoxetine 20 mg/day with olanzapine 5 mg once daily in the evening. Adjust dose as needed according to efficacy and tolerability (max, fluoxetine 75 mg/day, olanzapine 18 mg/day).Major Depressive DisorderAdults
PO Initial: 20 mg/day; increase after several weeks if insufficient clinical improvement noted (max, 80 mg/day). Weekly dosing (90 mg delayed-release capsule) may be started 7 days after last 20 mg/day dosage. If response is not satisfactory, consider reestablishing daily dosage regimen.Children 8 yr of age and older
PO Initial: 10 mg/day; increase after 1 wk (several weeks in lower-weight children) if insufficient clinical improvement noted (max, 20 mg/day).Obsessive-Compulsive DisorderAdults
PO Initial: 20 mg once daily in the morning; increase after several weeks if insufficient clinical improvement noted (max, 80 mg/day).Children 7 yr of age and older
PO Initial: 10 mg/day; increase after 2 wk (several weeks in lower-weight children) if insufficient clinical improvement noted (max, 60 mg/day).Panic DisorderAdults
PO Initial: 10 mg/day; increase to 20 mg/day after 1 wk. Further dose increases may be considered after several weeks if no clinical improvement noted (max, 60 mg/day).Premenstrual Dysphoric Disorder ( Sarafem and Selfemra only)Adults
PO Initial: 20 mg/day continuously (every day of menstrual cycle) or intermittently (starting 14 days prior to anticipated onset of menstruation through first full day of menses and repeating with each new cycle); dose may be increased if no clinical improvement noted (max, 80 mg/day).Treatment-Resistant DepressionAdults
PO Initial: fluoxetine 20 mg/day with olanzapine 5 mg once daily in the evening. Adjust dose as needed according to efficacy and tolerability (max, fluoxetine 75 mg/day, olanzapine 18 mg/day).
Store at 59° to 86°F. Protect from light.Selfemra
Store at 68° to 77°F. Protect from light.
Potentiation of impairment of cognitive and motor skills. Concurrent use is not recommended.Antipsychotics (eg, aripiprazole, clozapine, haloperidol, risperidone)
Serum levels may be increased. Elevated serum clozapine levels have occurred; closely monitor patients.Benzodiazepines
Coadministration of alprazolam and fluoxetine has resulted in increased alprazolam levels and decreased psychomotor performance. Halve the initial alprazolam dose and titrate to lowest effective dose. Diazepam half-life may be prolonged.Beta-blockers (eg, carvedilol, metoprolol, propranolol)
Elevated plasma concentrations of certain beta-blockers may occur, resulting in excessive beta-blockade.Buspirone
Effects of buspirone may be decreased.Carbamazepine
Increased carbamazepine levels, causing toxicity.CNS active drugs
Use with caution, titrating the dose and monitoring the clinical status of the patient.Cyclosporine
Concentrations of cyclosporine may be elevated, increasing the risk of toxicity.Cyproheptadine
Decreased or reversed effects of fluoxetine.Digoxin
The pharmacologic effects of digoxin may be increased, possibly because of displaced protein binding.Drugs metabolized by CYP2D6
Because fluoxetine inhibits CYP2D6, fluoxetine may cause patients with normal CYP2D6 metabolic activity to resemble poor metabolizers. Coadminister fluoxetine with caution to patients receiving drugs that are CYP2D6 substrates, especially drugs with a narrow therapeutic index (eg, flecainide, propafenone, vinblastine).5-HT 1 agonists (eg, sumatriptan)
Increased risk of serotonin syndrome (eg, hyperreflexia, incoordination, weakness) has been reported rarely.Hydantoins (eg, phenytoin)
Increased hydantoin levels, causing toxicity.Linezolid, metoclopramide, narcotic analgesics (eg, oxycodone), sibutramine, sympathomimetics (eg, amphetamine), tramadol
Risk of serotonin syndrome may be increased.Lithium
Lithium levels may be increased or decreased by fluoxetine, with possible neurotoxicity and increased serotonergic effects.MAOIs
Combination may lead to serious, possibly fatal, reactions. Discontinue MAOI at least 14 days before starting fluoxetine; discontinue fluoxetine at least 5 wk before starting MAOIs.Mirtazapine, olanzapine, propafenone, risperidone, valproic acid
Inhibition of metabolism by fluoxetine, resulting in elevated plasma concentrations and increasing the pharmacologic effects and risk of adverse reactions.NSAIDs (eg, aspirin, ibuprofen)
The risk of GI bleeding may be increased.Phosphodiesterase type 5 inhibitors (PDE5) (eg, sildenafil)
Metabolism inhibited by fluoxetine. Coadminister with caution; reduce initial dose of PDE5 inhibitor.Pimozide
A case of life-threatening sinus bradycardia has been reported. Coadministration is contraindicated.Protease inhibitors (eg, ritonavir)
Plasma concentrations of ritonavir and fluoxetine may be elevated, increasing the pharmacologic effects and adverse reactions of both agents. Risk of serotonin syndrome may be increased.Protein-bound drugs
Because fluoxetine is tightly bound to plasma protein, the risk of adverse reactions may be increased if fluoxetine is displaced from protein-binding sites by other tightly bound drugs.Serotonergic drugs
Because of the potential for serotonin syndrome, caution is advised when fluoxetine is administered with other drugs that may affect serotonergic neurotransmission (eg, lithium, St. John's wort, tramadol).Tamoxifen
Plasma levels may be decreased by fluoxetine. Coadminister with caution.Thioridazine
Concurrent use is contraindicated because of risk of prolongation of QTc interval and development of serious ventricular arrhythmias (eg, torsades de pointes) and sudden death.Trazodone
Plasma levels may be increased by fluoxetine; serotonin syndrome may occur.Tricyclic antidepressants
Increased toxic effects of tricyclic antidepressant. Dosage of tricyclic antidepressants may need to be reduced and plasma concentrations may need to be monitored when fluoxetine is coadministered or has been recently discontinued.Tryptophan
The risk of CNS symptoms and peripheral toxicity may be increased.Warfarin
The anticoagulant effects of warfarin may be increased, possibly because of displaced protein binding.
None well documented.
Vasodilation (5%); palpitations (3%); hemorrhage, hypertension (at least 1%); atrial fibrillation, heart arrest, QT prolongation, ventricular tachycardia including torsades de pointes–type arrhythmia (postmarketing).
Insomnia (33%); headache (24%); asthenia (21%); somnolence (17%); anxiety (15%); nervousness (14%); tremor (13%); decreased libido, dizziness (11%); abnormal thinking (6%); abnormal dreams (5%); agitation, hyperkinesia, personality disorder, thirst (at least 2%); amnesia, confusion, emotional lability, paresthesia, sleep disorder, suicidal ideation (at least 1%); cerebrovascular accident, dyskinesia, movement disorders, violent behaviors (postmarketing).
Sweating (8%); rash (6%); pruritus (3%); epidermal necrolysis, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, thrombocytopenic purpura (postmarketing).
Rhinitis (23%); pharyngitis (11%); abnormal vision (3%); epistaxis (at least 2%); ear pain, taste perversion, tinnitus (at least 1%); cataract (postmarketing).
Nausea (29%); diarrhea (18%); anorexia (17%); dry mouth (12%); dyspepsia (10%); abdominal pain (6%); constipation (5%); flatulence, vomiting (3%); increased appetite (at least 1%); pancreatitis (postmarketing).
Abnormal ejaculation, impotence (7%); menorrhagia, urinary frequency (at least 2%); gynecomastia, kidney failure, vaginal bleeding (postmarketing).
Aplastic anemia, immune-related hemolytic anemia, pancytopenia, thrombocytopenia (postmarketing).
Cholestatic jaundice, hepatic failure/necrosis (postmarketing).
Weight loss (3%); weight gain (at least 1%); hyperprolactinemia, hypoglycemia (postmarketing).
Yawn (11%); sinusitis (6%); eosinophilic pneumonia, pulmonary embolism, pulmonary hypertension (postmarketing).
Flu syndrome (12%); pain (9%); accidental injury (8%); infection (7%); fever (3%); chest pain, chills (at least 1%).
Compared with placebo, antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorders and other psychiatric disorders. Appropriately monitor and closely observe patients of all ages who are started on antidepressant therapy for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber.
Monitor all patients for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of therapy, or at times of dose changes, either increases or decreases. Frequently assess patient for response to treatment. Periodically review therapy to determine if therapy needs to be continued without change or if a dose change (eg, increase, decrease, discontinuation) is indicated. Monitor for signs and symptoms of hyponatremia, changes in weight, and for discontinuation symptoms if treatment is stopped.
Category C . Neonates exposed to fluoxetine late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Consider potential risks and benefits of treatment when treating women during the third trimester.
Excreted in breast milk.
Safety and efficacy have not been established in children younger than 8 yr of age with depression, or younger than 7 yr of age with OCD. Safety and efficacy not established ( Sarafem and Selfemra ).
No overall differences in safety and efficacy in patients 65 yr of age and older compared with younger subjects, but greater sensitivity cannot be ruled out.
Anaphylactoid reactions, including angioedema, bronchospasm, laryngospasm, and urticaria, alone and in combination, have been reported.
Use lower dose or less frequent dosing in patients with cirrhosis.
Use with caution in patients with diseases or conditions that could affect metabolism or hemodynamic response.
May impair judgment, thinking, or motor skills. Caution patients about operating potentially hazardous machinery (eg, driving) until they know whether the drug impairs their ability. Advise patients to avoid use of alcohol.
Bleeding episodes have occurred in patients treated with psychotropic drugs that interfere with serotonin reuptake.
Has been reported. Use cautiously in patients with history of mania.
Treatment-emergent anxiety, nervousness, or insomnia have been reported.
Withdrawal symptoms have been reported following rapid discontinuation of therapy. If treatment is to be discontinued, or the dose reduced, gradually taper the dose and monitor patient for withdrawal symptoms (eg, abnormal skin sensations, agitation, anxiety, confusion, dizziness, dysphoric mood, emotional lability, headaches, hypomania, insomnia, irritability, lethargy). If significant withdrawal symptoms develop, reinstitute previous dosing schedule and attempt a less rapid tapering regimen after patient has stabilized.
Because of the long elimination half-life of fluoxetine and norfluoxetine, changes in dose will not be fully reflected in plasma for several weeks, affecting titration to final dose and withdrawal from treatment.
Prolonged seizures have been reported in patients receiving concurrent electroconvulsive therapy treatment and fluoxetine.
Hypoglycemia has occurred during treatment with fluoxetine, and hyperglycemia has developed following discontinuation of fluoxetine. Dosage adjustment of insulin and/or oral hypoglycemic drugs may be necessary.
Hyponatremia and/or SIADH may occur. Use with caution in patients who are elderly or volume-depleted, or taking diuretics.
Has occurred and is potentially fatal. Signs and symptoms include altered mental status, diaphoresis, hyperpyrexia, irregular BP, irregular pulse, muscle rigidity, and tachycardia.
Various types of rashes and/or urticaria have been reported, some with systemic signs and symptoms (eg, arthralgia, edema, fever, lymphadenopathy, respiratory distress, vasculitis). Discontinue fluoxetine upon appearance of rash or other possibly allergic phenomena.
A major depressive episode may be the initial presentation of bipolar disorder. Treating such an episode with an antidepressant alone may increase the likelihood of precipitating a mixed/manic episode in patients at risk for bipolar disorder. Screen patients with depression for risk of bipolar disorder prior to initiating therapy with an antidepressant.
May occur; use with caution in patients with a history of seizures or with conditions that potentially lower the seizure threshold.
Development of a potentially life-threatening serotonin syndrome may occur with SSRIs, including fluoxetine, particularly with coadministration of serotonergic drugs (eg, 5-HT 1 agonists [eg, sumatriptan]) and with drugs that impair metabolism of serotonin (eg, MAOIs).
Weight gain, as well as decreased appetite and weight loss, may occur in adult patients. Decreased weight gain has been reported in children. Document patient weight prior to and periodically during prolonged treatment.
Events reported with overdose of fluoxetine, alone or coadministered with other drugs, include abnormal accommodation, abnormal gait, coma, confusion, death in children, delirium, ECG abnormalities (eg, QT interval prolongation), elevated BP, hypomania, hypotension, impotence, mania, movement disorder, nausea, nervousness, NMS-like reaction, pulmonary dysfunction, pyrexia, seizures, somnolence, stupor, syncope, tachycardia, tremor, unresponsiveness, vertigo, vomiting.
Copyright © 2009 Wolters Kluwer Health.